Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 30;23(1):9-19.
doi: 10.5056/jnm16124.

Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders

Hyo Jeong Lee  1 , Jong Kyoung Choi  2 , Han Seung Ryu  3 , Chang Hwan Choi  4 , Eun Hee Kang  1 , Kyung Sik Park  5 , Yang Won Min  6 , Kyoung Sup Hong  7
Affiliations
Review

Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders

Hyo Jeong Lee et al. J Neurogastroenterol Motil. .

Abstract

Functional bowel disorders (FBDs) are functional gastrointestinal disorders with symptoms attributable to the middle or lower gastrointestinal tract. These include irritable bowel syndrome, functional bloating, functional constipation, functional diarrhea, and unspecified FBD. Increasing evidence has emerged of late that intestinal microbiota is involved in the pathogenesis of FBDs. In this review, the therapeutic benefits and future perspectives of the currently available strategies for modifying the gut microbiota in FBDs are described, focusing primarily on irritable bowel syndrome and functional constipation.

Keywords: Diet; Fecal microbiota transplantation; Irritable bowel syndrome; Microbiota; Probiotics.

PubMed Disclaimer

References

    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. doi: 10.1053/j.gastro.2005.11.061. - DOI - PubMed
    1. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97:2290–2299. doi: 10.1111/j.1572-0241.2002.05783.x. - DOI - PubMed
    1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. doi: 10.1016/j.cgh.2012.02.029. - DOI - PubMed
    1. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–173. doi: 10.1038/nrgastro.2010.4. - DOI - PubMed
    1. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303:G775–G785. doi: 10.1152/ajpgi.00155.2012. - DOI - PubMed

LinkOut - more resources